Atrasentan in Patients With Proteinuric Glomerular Diseases
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 103 participants.
Also called NCT04573920
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 103 participants
- Sponsor
- Registry
-
NCT04573920
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Australia, Italy, South Korea, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04573920. Non-randomized; no masking; primary purpose treatment. Start 2021-03-15 (actual); primary completion 2024-07-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Atrasentan in Patients With Proteinuric Glomerular Diseases
- Acronym
- AFFINITY
- Condition
- IgA Nephropathy
- Condition
- Focal Segmental Glomerulosclerosis
- Condition
- Alport Syndrome
- Condition
- Diabetic Kidney Disease
- Condition
- Diabetic Nephropathy Type 2
- Condition
- Immunoglobulin A Nephropathy
- Intervention (Drug)
- Atrasentan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct04573920- Content hash
450080a1fff3a4ffeea4fe71735e1fa04758df3afa8f0f8a5a958b6c70155314